Thus, chloroquine and mycophenolate mofetil may be effective for patients with AIP and IgG4-RD as they would inhibit signaling pathways mediated by the activation of TLR7, TLR9, and IRF7. This evidence concerns the gene IRF7 and immunoglobulin G4-related sclerosing disease.